



# ichroma™ CA125

## INTENDED USE

**ichroma™ CA125** is a fluorescence Immunoassay (FIA) for the quantitative determination of CA125 (Cancer Antigen 125) in human serum/plasma. It is useful as an aid in management and monitoring of ovarian cancer.

For *in vitro* diagnostic use only.

## INTRODUCTION

Cancer antigen 125 (CA125), also called carbohydrate antigen 125, has played a most important role in the screening, detection and management of ovarian cancer.

CA125 is a high molecular weight glycoprotein. The amino acid analysis showed that CA125 has a high serine, threonine and proline content seen in mucin-like molecules.

CA125 test measures the amount of CA125 in the blood, and CA125 is a protein present on the surface of most ovarian cancer cells, and may be present in significantly increased concentrations in the blood of women with ovarian cancer. Sometimes, CA125 may indicate an increased value in ovarian cysts, endometriosis, uterus myomatosis or cervicitis, and may also be increased in diseases such as pancreatic cancer, lung cancer, breast cancer, colon cancer, gastrointestinal cancer, and liver cirrhosis as well as ovarian cancer.

Although the CA125 detection shows low specificity for screening or diagnosis of ovarian cancer, it can be usefully used for staging, prognosis, recurrence detection of therapeutic effects of ovarian cancer.

## PRINCIPLE

The test uses a sandwich immunodetection method.

The detector antibodies in buffer bind to antigens in the sample, forming antigen-antibody complexes, and migrate onto nitrocellulose matrix to be captured by the other immobilized streptavidin on a test strip.

More antigens in the sample will form more antigen-antibody complexes which lead to stronger fluorescence signal by detector antibodies, which is processed by the instrument for ichroma™ tests to show CA125 concentration in the sample.

## COMPONENTS

**ichroma™ CA125** consists of 'cartridges', 'detector tubes' and 'detector diluent'.

- The cartridge contains the membrane called a test strip which has streptavidin at the test line and chicken IgY at the control line. All cartridges are individually sealed in an aluminum foil pouch containing a desiccant, and they are further packaged in a box.
- The detector tube has 2 granules containing anti-CA125-fluorescence conjugate, anti-CA125-Biotin conjugate, anti-

chicken IgY-fluorescence conjugate and sodium azide as a preservative in MES buffer. All detector tubes are packed in a pouch.

- The detector diluent contains tween 20 as a detergent, sodium azide as a preservative in phosphate buffered saline (PBS), and it is pre-dispensed in a vial. The detector diluent is packed in a box.

## WARNINGS AND PRECAUTIONS

- For *in vitro* diagnostic use only.
- Follow instructions and procedures described in this 'Instructions for use'.
- Use only fresh samples and avoid direct sunlight.
- Lot numbers of all the test components (cartridge, detector tube, detector diluent, and ID chip) must match each other.
- Do not interchange the test components between different lots or use the test components after the expiration date, either of which might yield incorrect test result(s).
- Do not reuse cartridges or detector tubes. A cartridge should be used for testing one sample only. A detector tube should be used for processing of one sample only.
- The cartridge should remain sealed in its original pouch until just before use. Do not use cartridge if pouch is damaged or has already been opened.
- Frozen sample should be thawed only once. For shipping, samples must be packed in accordance with local regulations. Sample with severe hemolysis and/or hyperlipidemia must not be used.
- If test components and/or sample are stored in refrigerator, then allow cartridge, detector tube, detector diluent and sample to be at room temperature for approximately 30 minutes before use.
- The instrument for ichroma™ tests may generate slight vibration during use.
- Used cartridges, detector tubes, detector diluent and pipette tips should be handled carefully and discarded by an appropriate method in accordance with relevant local regulations.
- The detector tube and the detector diluent contain sodium azide (NaN<sub>3</sub>), and it may cause certain health issues like convulsions, low blood pressure, low heart rate, loss of consciousness, lung injury and respiratory failure. Avoid contact with skin, eyes, and clothing. In case of contact, rinse immediately with running water.
- No Biotin interference was observed in ichroma™ CA125 when biotin concentration in the sample was below 100 ng/mL. If a patient has been taking biotin at dosage of more than 0.03 mg a day, it is recommended to test again 24 hours after discontinuation of biotin intake.
- ichroma™ CA125 will provide accurate and reliable results subject to the below conditions.
  - **ichroma™ CA125** should be used only in conjunction with the instrument for ichroma™ tests.
  - Have to use recommended anticoagulant.

Recommended anticoagulant

K<sub>2</sub>EDTA, K<sub>3</sub>EDTA, Sodium heparin

### LIMITATION OF THE TEST SYSTEM

- The test may yield false positive result(s) due to the cross reactions and/or non-specific adhesion of certain sample components to the capture/detector antibodies.
- The test may yield false negative result(s) due to the non-responsiveness of the antigens to the antibodies which is the most common if the epitope is masked by some unknown components, so therefore not being able to be detected or captured by the antibodies. The instability or degradation of the antigens with time and/or temperature may also cause false negative result as it makes the antigens unrecognizable by the antibodies.
- Other factors may interfere with the test and cause erroneous results, such as technical/procedural errors, degradation of the test components/reagents or presence of interfering substances in the test samples.
- Any clinical diagnosis based on the test result must be supported by a comprehensive judgment of the concerned physician in conjunction with clinical symptoms and other relevant test results.

### STORAGE AND STABILITY

Storage condition			
Component	Storage Temperature	Shelf life	Note
Cartridge	2 - 30 °C	20 months	Disposable
Detector tube	2 - 30 °C	20 months	Disposable
Detector diluent	2 - 30 °C	20 months	Unopened
	2 - 30 °C	20 months	Opened

- After the cartridge pouch is opened, the test should be performed immediately.

### MATERIALS SUPPLIED

**REF** CFPC-160

Component of **ichroma™ CA125**

- Cartridge box:
  - Cartridge 25
  - Detector tube 25
  - Detector diluent 1
  - ID chip 1
  - Instructions for use 1

### MATERIALS REQUIRED BUT SUPPLIED ON DEMAND

Following items can be purchased separately from **ichroma™ CA125**.

Please contact our sales division for more information.

- Instrument for **ichroma™** tests
  - **ichroma™ II** **REF** FPRR021
  - **ichroma™ III** **REF** FPRR037
  - **ichroma™-50 PLUS** **REF** FPRR036
  - **ichroma™ M2** **REF** FPRR031
- **Boditech CA125 Control** **REF** CFPO-359

### SAMPLE COLLECTION AND PROCESSING

The sample type for **ichroma™ CA125** is human serum/plasma.

- It is recommended to test the sample within 24 hours after collection when collected sample is stored at room temperature.
- The samples (serum, plasma) should be separated from the clot by centrifugation within 3 hours after the collection of whole blood.
- The samples (serum, plasma) maybe stored for a week at 2-8°C prior to being tested. If testing will be delayed more than a week, samples (serum, plasma) should be frozen at -20°C.
- The samples (serum, plasma) stored frozen at -20°C for 3 months showed no performance difference.
- As a repeated freeze-thaw cycle may affect the test result, do not refreeze previously frozen samples.

### TEST SETUP

- Check the contents of **ichroma™ CA125**: Sealed cartridges, detector tubes, a detector diluent, an ID chip and an instructions for use.
- Ensure that the lot number of the cartridge matches that of the detector tubes, the detector diluent as well as ID chip.
- If the sealed cartridge, the detector tube and the detector diluent have been stored in a refrigerator, place them on a clean and flat surface at room temperature for at least 30 minutes before testing.
- Turn on the instrument for **ichroma™** tests.
- Insert the ID chip into the 'ID chip port'.

※ Please refer to the instrument for **ichroma™** tests operation manual for the complete information and operating instructions.

### TEST PROCEDURE

#### ► **ichroma™ II, ichroma™ M2**

#### **Multi test mode/ Read now mode**

- 1) Select the sample type (serum/plasma) on the screen.
- 2) Take 150 µL of detector diluent using a pipette and dispense it to the detector tube containing granules. When the granule form is completely dissolved in the tube, it becomes detection buffer. (The detection buffer must be used immediately. Do not exceed 30 seconds.)
- 3) Take 30 µL of sample (serum/plasma/control) using a pipette and dispense it to the detector tube.
- 4) Close the lid of the detector tube and mix the sample thoroughly by shaking it about 20 times. (The sample mixture must be used immediately. Do not exceed 30 seconds.)
- 5) Take 75 µL of the sample mixture and dispense it into the sample well of the cartridge.
- 6) Leave the cartridge at room temperature for 12 minutes.
  - ⚠ Scan the sample-loaded cartridge immediately when the incubation time is over. If not, it will cause inaccurate test result.

- 7) To scan the sample-loaded cartridge, insert it into the cartridge holder of the instrument for ichroma™ tests. Ensure proper orientation of the cartridge before pushing it all the way inside the cartridge holder. An arrow is marked on the cartridge especially for this purpose.
- 8) Press the 'Select' or tap the 'Start' button on the instrument for ichroma™ tests to start the scanning process. (ichroma™ M2 will start the test automatically after inserting.)
- 9) The instrument for ichroma™ tests will start scanning the sample-loaded cartridge immediately.
- 10) Read the test result on the display screen of the instrument for ichroma™ tests.

#### Single test mode/ Walk away mode

- 1) The test procedure is same with the 'Multi test mode 1) - 5)'.
  - 2) Insert the sample-loaded cartridge into the holder of the instrument for ichroma™ tests. Ensure proper orientation of the cartridge before pushing it all the way inside the cartridge holder. An arrow is marked on the cartridge especially for this purpose.
- 3) Press the 'Select' or tap the 'Start' button on the instrument for ichroma™ test. (ichroma™ M2 will start the test automatically after inserting.)
- 4) The cartridge goes inside the instrument for ichroma™ tests and will automatically start scanning the sample-loaded cartridge after 12 minutes.
- 5) Read the test result on the display screen of the instrument for ichroma™ tests.

#### ▶ ichroma™ III

- 1) The test procedure is same with the 'Single test mode'.

#### ▶ ichroma™-50 PLUS

- 1) Insert the tip array in the tip station.
- 2) Insert the detector tube in the reagent station and cover the reagent station to hold the detector tubes in place.
- 3) Open the lid of the detector diluent and insert the detector diluent in the diluent station.
- 4) Insert the cartridge magazine with the cartridges into the magazine station.
- 5) Insert the sample tube into the blood collection tube rack and load the blood collection tube rack into the sampling station (loading part).
- 6) Tap the button located in the upper side of the No. of test cartridge region to select the ID chip that you want to use.
- 7) When the selected cartridge slot is activated, set the number of the detector tube by tapping.
- 8) Set the number of pipette tips by tapping.
- 9) Select the sample type (serum/plasma) on the screen.
- 10) Tap the 'Start' button on the left upper of the main screen to start test.

#### INTERPRETATION OF TEST RESULT

- The instrument for ichroma™ tests calculates the test result automatically and displays CA125 concentration of

the test sample in terms of U/mL.

- Working range: 5 - 700 U/mL
- Cut-off : 35 U/mL

#### QUALITY CONTROL

- Quality control tests are a part of the good testing practice to confirm the expected results and validity of the assay and should be performed at regular intervals.
- Quality control tests should also be performed whenever there is any question concerning the validity of the test results.
- Control materials are not provided with ichroma™ CA125. For more information regarding obtaining the control materials, contact [Boditech Med Inc.'s Sales Division for assistance](#). (Please refer to the instruction for use of control material.)

#### PERFORMANCE CHARACTERISTICS

##### ▪ Analytical sensitivity

- Limit of Blank (LoB) 1.4 U/mL
- Limit of Detection (LoD) 2.1 U/mL
- Limit of Quantitation (LoQ) 5.0 U/mL

##### ▪ Analytical specificity

- Cross reactivity  
 Biomolecules listed in the following table were added to the test sample(s) at concentrations much higher than their normal physiological levels in the blood. **ichroma™ CA125** test results did not show any significant cross-reactivity with these biomolecules.

Cross- reactants	Concentration
CA15-3	1000 U/mL
CA19-9	3700 U/mL
Cyfra 21-1	3300 U/mL
CEA	500 ng/mL

- Interference  
 Interferents listed in the following table were added to the test sample at the concentration mentioned below. **ichroma™ CA125** test results did not show any significant interference with these materials.

Interferents	Concentration
Hemoglobin	1000 mg/dL
Bilirubin (unconjugated)	40 mg/dL
Triglycerides, total	1600 mg/dL
Biotin	100 ng/mL

##### ▪ Precision

- Single-site study  
Repeatability (within-run precision)  
within-laboratory precision (Total precision)  
Lot to lot precision

3 Lots of **ichroma™ CA125** were tested for 20 days. Each standard material was tested 2 times per day. For each test, each material was duplicated.

CA125 [U/mL]	Single-site study					
	Repeatability		within-laboratory precision		Lot to lot precision	
	AVG [U/mL]	CV (%)	AVG [U/mL]	CV (%)	AVG [U/mL]	CV (%)
30	31.24	7.0	31.28	6.6	31.14	5.7
100	103.40	5.3	102.46	4.6	102.01	4.9
250	244.92	4.3	243.55	4.1	245.17	4.4

- Multi-site study

Reproducibility

1 Lot of **ichroma™ CA125** was tested for 5 days in 3 different sites (1 person per 1 site, 1 instrument per 1 site). Each standard material was tested 1 time per and 5 replicates per day.

Multi-site study		
CA125 [U/mL]	Reproducibility	
	AVG [U/mL]	CV (%)
30	29.68	5.9
100	102.21	5.7
250	253.13	4.0


■ Accuracy

The accuracy was confirmed by 3 different lots of **ichroma™ CA125**. The tests were repeated 10 times at each concentration of the control standard.

CA125 [U/mL]	Lot 1	Lot 2	Lot 3	AVG [U/mL]	Recovery (%)
500.0	480.69	482.49	492.72	485.30	97%
406.0	413.52	404.34	416.47	411.44	101%
312.0	326.72	332.88	317.47	325.69	104%
218.0	224.61	217.49	222.50	221.53	102%
124.0	119.37	122.89	122.06	121.44	98%
30.0	28.94	28.83	28.50	28.76	96%

■ Comparability

CA125 concentrations of 100 clinical samples were quantified independently with **ichroma™ CA125 (ichroma™ II)** and Comparator A as per prescribed test procedures. Test results were compared, and their comparability was investigated with linear regression and correlation coefficient (R). The regression equation and correlation coefficient are as follows.



**REFERENCES**

1. Parsa Charkhchi et al. CA125 and Ovarian Cancer: A Comprehensive Review. *Cancers* 2020, 12(12), 3730
2. Lloyd, K.O et al. Isolation and Characterization Of Ovarian Cancer Antigen CA 125 Using A New Monoclonal Antibody (VK-8): Identification As a Mucin-Type Molecule. *Int. J. Cancer* 1997, 71, 842–850.
3. Alessandro Bressan et al. OC125, M11 and OV197 epitopes are not uniformly distributed in the tandem-repeat region of CA125 and require the entire SEA domain. *Disease Markers* 34 (2013) 257–267

4. P.M. FAYERS et al. The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer. *Int J Gynecol Cancer*, 1993, 3, 285-292
5. Mildred Felder et al. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. *Molecular Cancer* 2014, 13:129
6. Nathalie Scholler and Nicole Urban. CA125 in Ovarian Cancer. *Biomark Med.* 2007 December ; 1(4): 513–523.
7. Joseph Menczer, M.D. et al. The Significance of Normal Pretreatment Levels of CA125 (<35 U/mL) in Epithelial Ovarian Carcinoma. *Rambam Maimonides Medical J.* 2015 jan 29;6(1)

**Note:** Please refer to the table below to identify various symbols

	Sufficient for <n> tests
	Read instruction for use
	Use by Date
	Batch code
	Catalog number
	Caution
	Manufacturer
	Authorized representative of the European Community
	In vitro diagnostic medical device
	Temperature limit
	Do not reuse
	This product fulfills the requirements of the Directive 98/79/EC on in vitro diagnostic medical devices

For technical assistance; please contact:

**Boditech Med Inc.'s Technical Sales**

Tel: +(82)-33-243-1400

E-mail: TS@boditech.co.kr

 **Boditech Med Inc.**

43, Geodudanji 1-gil, Dongnae-myeon, Chuncheon-si, Gang-won-do, 24398, Republic of Korea

Tel: +(82) -33-243-1400

Fax: +(82) -33-243-9373

www.boditech.co.kr

 **Obelis s.a**

Bd. Général Wahis 53, 1030 Brussels, Belgium

Tel: +(32) -2-732-59-54

Fax: +(32) -2-732-60-03

E-Mail: mail@obelis.net

